Effect of Immunosuppressive Therapies for the Treatment of Inflammatory Bowel Disease on Response to Routine Vaccinations: A Meta-Analysis (Q46205741)

20 December 2017

meta-analysis

0 references

title

Effect of Immunosuppressive Therapies for the Treatment of Inflammatory Bowel Disease on Response to Routine Vaccinations: A Meta-Analysis (English)

1 reference

20 December 2017

inflammatory bowel diseases

main subject

0 references

author name string

Douglas L Nguyen

series ordinal

1

1 reference

20 December 2017

Emily T Nguyen

series ordinal

2

1 reference

20 December 2017

Matthew L Bechtold

series ordinal

3

1 reference

20 December 2017

publication date

22 March 2015

1 reference

20 December 2017

Digestive Diseases and Sciences

published in

1 reference

20 December 2017

volume

60

1 reference

20 December 2017

issue

8

1 reference

20 December 2017

page(s)

2446-2453

1 reference

20 December 2017

https://scigraph.springernature.com/pub.10.1007/s10620-015-3631-y

exact match

0 references

cites work

Antitumor necrosis factor α is more effective than conventional medical therapy for the prevention of postoperative recurrence of Crohn's disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Immunizations in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Inadequate knowledge of immunization guidelines: a missed opportunity for preventing infection in immunocompromised IBD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Guidelines for immunizations in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Appropriate response to influenza A (H1N1) virus vaccination in patients with inflammatory bowel disease on maintenance immunomodulator and/or biological therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Factors predicting response to hepatitis B vaccination in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Efficacy of hepatitis A vaccination and factors impacting on seroconversion in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Risk factors for opportunistic infections in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Mortality by medication use among patients with inflammatory bowel disease, 1996-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

A practical guide to vaccinating the inflammatory bowel disease patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3631-Y

21 January 2018

1 reference

12 December 2020

Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.

1 reference

12 December 2020

Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study*

1 reference

12 December 2020

Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)

1 reference

12 December 2020

Kinetics of Anti–Hepatitis B Surface Antigen Titers After Hepatitis B Vaccination in Patients With Inflammatory Bowel Disease

1 reference

12 December 2020

10.1007/S10620-015-3631-Y

Identifiers

DOI

1 reference

20 December 2017

release_mtqopmz4ibfs7fz6gl2oundsqe

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mtqopmz4ibfs7fz6gl2oundsqe

24 November 2022

mapped directly with Wikidata item

1 reference

20 December 2017